TB4-Frag Evidence Guide
Evidence for TB4-Frag is too preliminary to support a research protocol with confidence. There is no peer-reviewed published evidence for this specific thymosin beta-4 fragment in any therapeutic context. Thymosin beta-4 itself (the parent molecule) has more published preclinical data. This compound should not be selected over TB4 or other healing peptides with any actual evidence base.
Our Take
Evidence for TB4-Frag is too preliminary to support a research protocol with confidence. There is no peer-reviewed published evidence for this specific thymosin beta-4 fragment in any therapeutic context. Thymosin beta-4 itself (the parent molecule) has more published preclinical data. This compound should not be selected over TB4 or other healing peptides with any actual evidence base.
- Evidence context
- No validated application - TB4 fragment mechanistic curiosity only
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human protocol and no peer-reviewed dosing guidance
Benefits and Evidence
- Anti-Fibrotic Activity: Level D, mostly non-human evidence - Animal studies demonstrate significant reduction in cardiac, renal, and hepatic fibrosis. Collagen deposition is reduced by 30-50% in treated animals compared to controls.
- Cardiac Function Preservation: Level D, mostly non-human evidence - Preclinical models of heart failure show preserved ejection fraction and reduced ventricular remodeling with continuous Ac-SDKP/TB4-Frag infusion.
- Stem Cell Protection During Chemotherapy: Level D, mostly non-human evidence - Animal studies indicate protection of bone marrow stem cells from chemotherapy-induced depletion, potentially accelerating hematological recovery.
Side Effects and Warnings
- No significant adverse effects in animal studies
- Theoretical risk of hypotension
- Potential interaction with blood pressure regulation
- Very limited safety data
- Not approved for any clinical use
- Extremely short half-life limits practical application without continuous infusion or ACE inhibitor co-therapy
- Identical active molecule to Ac-SDKP; sourcing and nomenclature may overlap
- All evidence is preclinical
Research Dosage References
- <strong>Subcutaneous injection</strong> - 100-500 mcg - Daily - Experimental dosing extrapolated from animal studies. Rapid ACE-mediated degradation may require frequent dosing or co-administration with ACE inhibitors.
Mechanism of Action
TB4-Frag exerts its effects through mechanisms identical to Ac-SDKP: 1. Collagen synthesis inhibition: Suppresses TGF-beta1-mediated collagen type I and III production by cardiac and renal fibroblasts. 2. Smad pathway modulation: Inhibits Smad2/3 phosphorylation, blocking the pro-fibrotic signaling cascade. 3. Stem cell quiescence maintenance: Keeps hematopoietic stem cells in G0 phase, protecting them from cell cycle-dependent cytotoxic damage. 4. Inflammatory macrophage suppression: Shifts macrophage polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotype in injured tissues.
Legal Status
TB4-Frag/Ac-SDKP is a research compound not approved for clinical use. The name is used for the Ac-SDKP tetrapeptide, but product identity should be verified rather than inferred from a catalog label.
Primary Sources
Quick Answers
Where is the strongest evidence for TB4-Frag?
Evidence for TB4-Frag is too preliminary to support a research protocol with confidence. There is no peer-reviewed published evidence for this specific thymosin beta-4 fragment in any therapeutic context. Thymosin beta-4 itself (the parent molecule) has more published preclinical data. This compound should not be selected over TB4 or other healing peptides with any actual evidence base. Evidence context: No validated application - TB4 fragment mechanistic curiosity only.
What are the main side effects of TB4-Frag?
TB4-Frag side effects and warning signals include No significant adverse effects in animal studies, Theoretical risk of hypotension, Potential interaction with blood pressure regulation, Very limited safety data, and Not approved for any clinical use.
What evidence level is TB4-Frag?
TB4-Frag is rated Level D; the listed research status is Preclinical.